Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects

Weihua Yue, Guolian Kang, Yanbo Zhang, Mei Qu, Fulei Tang, Yonghua Han, Yan Ruan, Tianlan Lu, Jifeng Zhang, Dai Zhang

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The present study examined the correlation between variants in the d-amino acid oxidase activator (DAOA) locus and clinical symptoms and response to antipsychotics in schizophrenia. Case-control analysis and the family-based association test (FBAT) were performed to investigate whether four single nucleotide polymorphisms (SNPs) at DAOA gene are associated with schizophrenia. The association between the DAOA risk haplotype and clinical symptoms were examined by the positive and negative syndrome scale (PANSS) and the brief psychiatric rating scale (BPRS). Our findings showed that the SNP rs947267 was significantly associated with schizophrenia in both case control and familial trio samples (A > C, χ 2 = 8.36, p = 0.004; Z = 2.335, p = 0.019), as well as with specific haplotypes, in particular those formed by the A allele of rs947267. In addition, the risk haplotype AAG was significantly correlated with negative, depression and cognitive impairment factors of PANSS, even with the BPRS change scores after 6-week treatment of atypical antipsychotic drugs (p < 0.05). These results support the hypothesis that variations in DAOA may play a role in schizophrenia and clinical characteristics.

Original languageEnglish (US)
Pages (from-to)96-100
Number of pages5
JournalNeuroscience Letters
Volume416
Issue number1
DOIs
StatePublished - Apr 6 2007
Externally publishedYes

Fingerprint

Therapeutic Uses
Schizophrenia
Oxidoreductases
Haplotypes
Brief Psychiatric Rating Scale
Amino Acids
Antipsychotic Agents
Single Nucleotide Polymorphism
Alleles
Depression
Genes
Therapeutics

Keywords

  • Association study
  • Clinical symptom
  • DAOA
  • Schizophrenia
  • Therapeutic effect

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects. / Yue, Weihua; Kang, Guolian; Zhang, Yanbo; Qu, Mei; Tang, Fulei; Han, Yonghua; Ruan, Yan; Lu, Tianlan; Zhang, Jifeng; Zhang, Dai.

In: Neuroscience Letters, Vol. 416, No. 1, 06.04.2007, p. 96-100.

Research output: Contribution to journalArticle

Yue, W, Kang, G, Zhang, Y, Qu, M, Tang, F, Han, Y, Ruan, Y, Lu, T, Zhang, J & Zhang, D 2007, 'Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects', Neuroscience Letters, vol. 416, no. 1, pp. 96-100. https://doi.org/10.1016/j.neulet.2007.01.056
Yue, Weihua ; Kang, Guolian ; Zhang, Yanbo ; Qu, Mei ; Tang, Fulei ; Han, Yonghua ; Ruan, Yan ; Lu, Tianlan ; Zhang, Jifeng ; Zhang, Dai. / Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects. In: Neuroscience Letters. 2007 ; Vol. 416, No. 1. pp. 96-100.
@article{f555faac40a9448ba5533809fffaa84d,
title = "Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects",
abstract = "The present study examined the correlation between variants in the d-amino acid oxidase activator (DAOA) locus and clinical symptoms and response to antipsychotics in schizophrenia. Case-control analysis and the family-based association test (FBAT) were performed to investigate whether four single nucleotide polymorphisms (SNPs) at DAOA gene are associated with schizophrenia. The association between the DAOA risk haplotype and clinical symptoms were examined by the positive and negative syndrome scale (PANSS) and the brief psychiatric rating scale (BPRS). Our findings showed that the SNP rs947267 was significantly associated with schizophrenia in both case control and familial trio samples (A > C, χ 2 = 8.36, p = 0.004; Z = 2.335, p = 0.019), as well as with specific haplotypes, in particular those formed by the A allele of rs947267. In addition, the risk haplotype AAG was significantly correlated with negative, depression and cognitive impairment factors of PANSS, even with the BPRS change scores after 6-week treatment of atypical antipsychotic drugs (p < 0.05). These results support the hypothesis that variations in DAOA may play a role in schizophrenia and clinical characteristics.",
keywords = "Association study, Clinical symptom, DAOA, Schizophrenia, Therapeutic effect",
author = "Weihua Yue and Guolian Kang and Yanbo Zhang and Mei Qu and Fulei Tang and Yonghua Han and Yan Ruan and Tianlan Lu and Jifeng Zhang and Dai Zhang",
year = "2007",
month = "4",
day = "6",
doi = "10.1016/j.neulet.2007.01.056",
language = "English (US)",
volume = "416",
pages = "96--100",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects

AU - Yue, Weihua

AU - Kang, Guolian

AU - Zhang, Yanbo

AU - Qu, Mei

AU - Tang, Fulei

AU - Han, Yonghua

AU - Ruan, Yan

AU - Lu, Tianlan

AU - Zhang, Jifeng

AU - Zhang, Dai

PY - 2007/4/6

Y1 - 2007/4/6

N2 - The present study examined the correlation between variants in the d-amino acid oxidase activator (DAOA) locus and clinical symptoms and response to antipsychotics in schizophrenia. Case-control analysis and the family-based association test (FBAT) were performed to investigate whether four single nucleotide polymorphisms (SNPs) at DAOA gene are associated with schizophrenia. The association between the DAOA risk haplotype and clinical symptoms were examined by the positive and negative syndrome scale (PANSS) and the brief psychiatric rating scale (BPRS). Our findings showed that the SNP rs947267 was significantly associated with schizophrenia in both case control and familial trio samples (A > C, χ 2 = 8.36, p = 0.004; Z = 2.335, p = 0.019), as well as with specific haplotypes, in particular those formed by the A allele of rs947267. In addition, the risk haplotype AAG was significantly correlated with negative, depression and cognitive impairment factors of PANSS, even with the BPRS change scores after 6-week treatment of atypical antipsychotic drugs (p < 0.05). These results support the hypothesis that variations in DAOA may play a role in schizophrenia and clinical characteristics.

AB - The present study examined the correlation between variants in the d-amino acid oxidase activator (DAOA) locus and clinical symptoms and response to antipsychotics in schizophrenia. Case-control analysis and the family-based association test (FBAT) were performed to investigate whether four single nucleotide polymorphisms (SNPs) at DAOA gene are associated with schizophrenia. The association between the DAOA risk haplotype and clinical symptoms were examined by the positive and negative syndrome scale (PANSS) and the brief psychiatric rating scale (BPRS). Our findings showed that the SNP rs947267 was significantly associated with schizophrenia in both case control and familial trio samples (A > C, χ 2 = 8.36, p = 0.004; Z = 2.335, p = 0.019), as well as with specific haplotypes, in particular those formed by the A allele of rs947267. In addition, the risk haplotype AAG was significantly correlated with negative, depression and cognitive impairment factors of PANSS, even with the BPRS change scores after 6-week treatment of atypical antipsychotic drugs (p < 0.05). These results support the hypothesis that variations in DAOA may play a role in schizophrenia and clinical characteristics.

KW - Association study

KW - Clinical symptom

KW - DAOA

KW - Schizophrenia

KW - Therapeutic effect

UR - http://www.scopus.com/inward/record.url?scp=33947251327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947251327&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2007.01.056

DO - 10.1016/j.neulet.2007.01.056

M3 - Article

VL - 416

SP - 96

EP - 100

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1

ER -